An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat.
Paclitaxel (Taxol) is a frontline antineoplastic agent used to treat a variety of solid tumors including breast, ovarian, or lung cancer. The major dose limiting side effect of paclitaxel is a peripheral sensory neuropathy that can last days to a lifetime. To begin to understand the cellular events that contribute to this neuropathy, we examined a marker of cell injury/regeneration (activating transcription factor 3; ATF3), macrophage hyperplasia/hypertrophy; satellite cell hypertrophy in the dorsal root ganglia (DRG) and sciatic nerve as well as astrocyte and microglial activation within the spinal cord at 1, 4, 6 and 10 days following intravenous infusion of therapeutically relevant doses of paclitaxel. At day 1 post-infusion, there was an up-regulation of ATF3 in a subpopulation of large and small DRG neurons and this up-regulation was present through day 10. In contrast, hypertrophy of DRG satellite cells, hypertrophy and hyperplasia of CD68(+) macrophages in the DRG and sciatic nerve, ATF3 expression in S100beta(+) Schwann cells and increased expression of the microglial marker (CD11b) and the astrocyte marker glial fibrillary acidic protein (GFAP) in the spinal cord were not observed until day 6 post-infusion. The present results demonstrate that using the time points and markers examined, DRG neurons show the first sign of injury which is followed days later by other neuropathological changes in the DRG, peripheral nerve and dorsal horn of the spinal cord. Understanding the cellular changes that generate and maintain this neuropathy may allow the development of mechanism-based therapies to attenuate or block this frequently painful and debilitating condition.
Peters
Christopher M
CM
Department of Diagnostic & Biological Sciences, University of Minnesota, Minneapolis, MN 55455, USA.
Jimenez-Andrade
Juan Miguel
JM
Kuskowski
Michael A
MA
Ghilardi
Joseph R
JR
Mantyh
Patrick W
PW
D051700:Activating Transcription Factor 3 / Q000378:metabolism; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001253:Astrocytes / Q000187:drug effects; D048429:Cell Size / Q000187:drug effects; D005727:Ganglia, Spinal / Q000187:drug effects* / Q000473:pathology; D005786:Gene Expression Regulation / Q000187:drug effects; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D007276:Injections, Intraventricular / Q000379:methods; D008264:Macrophages / Q000187:drug effects / Q000473:pathology; D008297:Male; D008954:Models, Biological; D017239:Paclitaxel / Q000008:administration & dosage*; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000187:drug effects* / Q000473:pathology; D013116:Spinal Cord / Q000187:drug effects* / Q000473:pathology; D018709:Statistics, Nonparametric; D013997:Time Factors; D000097382:CD68 Molecule
D051700:Activating Transcription Factor 3; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000972:Antineoplastic Agents, Phytogenic; D005904:Glial Fibrillary Acidic Protein; D017239:Paclitaxel; D010751:Phosphopyruvate Hydratase; C497108:Atf3 protein, rat; C067980:CD68 antigen, human; D000097382:CD68 Molecule
Ann Oncol. 1995 May;6(5):489-94
7669713
Eur J Cancer. 2005 Jul;41(10):1460-6
15913989
Exp Neurol. 1996 Sep;141(1):94-101
8797671
J Comp Neurol. 1997 Mar 17;379(3):428-42
9067834
Pain. 1997 Feb;69(3):317-22
9085307
Ann Neurol. 1998 Jan;43(1):46-55
9450768
Neuropathol Appl Neurobiol. 1999 Feb;25(1):29-40
10194773
Eur J Neurosci. 1999 May;11(5):1711-22
10215925
J Neurosci Res. 1999 Oct 1;58(1):33-41
10491570
Trends Neurosci. 2005 Feb;28(2):101-7
15667933
Exp Neurol. 2005 May;193(1):85-100
15817267
Eur J Cancer. 2006 Jan;42(1):24-30
16293411
Acta Neuropathol. 1999 Dec;98(6):651-3
10603043
Mol Cell Neurosci. 2000 Feb;15(2):170-82
10673325
Neurotoxicology. 2000 Jun;21(3):389-93
10894128
Pain. 2000 Dec 1;88(3):239-48
11068111
Pain. 2001 Apr;91(3):351-60
11275393
Trends Neurosci. 2001 Aug;24(8):450-5
11476884
Eur J Neurosci. 2002 Mar;15(6):1037-47
11918652
J Neurol. 2002 Jan;249(1):9-17
11954874
Neuroscience. 2002;112(1):23-38
12044469
J Neurosci. 2002 Aug 1;22(15):6696-703
12151548
Pain. 2003 Jan;101(1-2):65-77
12507701
Lab Invest. 2003 Feb;83(2):175-85
12594233
J Neurosci. 2003 May 15;23(10):4017-22
12764087
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7947-52
12808141
Nature. 2003 Aug 14;424(6950):778-83
12917686
Neuroscience. 2003;121(3):691-704
14568029
Neuroscience. 2003;121(3):815-24
14568039
Brain. 2004 Mar;127(Pt 3):671-9
14761904
Eur J Neurosci. 2004 Mar;19(6):1437-45
15066140
Pain. 2004 May;109(1-2):132-42
15082135
Brain Res. 1982 Feb 25;234(2):309-17
7059833
J Neurocytol. 1984 Apr;13(2):187-200
6726286
J Neurocytol. 1984 Dec;13(6):923-34
6398831
Proc Natl Acad Sci U S A. 1986 Jun;83(11):4094-8
3012551
J Comp Neurol. 1987 Jun 8;260(2):246-55
3038969
Nature. 1987 Dec 17-23;330(6149):658-9
3317065
J Comp Neurol. 1987 Dec 8;266(2):183-97
2830320
J Comp Neurol. 1988 Sep 15;275(3):460-8
3225349
Neurosci Lett. 1989 Mar 13;98(1):8-12
2710403
Peptides. 1990 Jul-Aug;11(4):719-28
1978300
J Cell Biol. 1992 Oct;119(1):45-54
1527172
Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15
8102012
Arch Neurol. 1994 Jul;51(7):726-9
7912506
Exp Neurol. 1994 Oct;129(2):237-43
7957738
J Neurocytol. 1994 Sep;23(9):515-31
7815085
Immunology. 1994 Sep;83(1):140-7
7821959
Exp Neurol. 1995 Jan;131(1):11-22
7895805
Exp Neurol. 1995 May;133(1):64-72
7601264
J Natl Cancer Inst. 1995 Jul 19;87(14):1077-81
7616600
Eur J Neurosci. 2006 Jan;23(2):365-73
16420444
BMC Cancer. 2006;6:5
16398939
J Natl Cancer Inst. 2006 Mar 15;98(6):382-8
16537830
J Clin Oncol. 2006 Apr 1;24(10):1633-42
16575015
Anticancer Res. 2006 Mar-Apr;26(2A):1065-70
16619507
Mol Cell Neurosci. 2006 May-Jun;32(1-2):143-54
16713293
Neurosci Lett. 2006 Sep 11;405(1-2):62-7
16854522
Nat Rev Neurosci. 2006 Oct;7(10):797-809
16988655
Neuroscience. 2006 Oct 27;142(3):809-22
16887276
Exp Neurol. 2007 Jan;203(1):42-54
17005179
Brain Res Brain Res Rev. 2005 Jun;48(3):457-76
15914252
Neuroreport. 1996 Mar 22;7(4):857-60
8724660